Response to Comments: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer

This document is an administrative response noting that no provider comments were received for MolDX DL38329 and announcing the notice period (beginning 07/09/2020) and effective date (08/24/2020). The LCD title was changed from 'MolDX: Razor 14-Gene Lung Cancer Assay' to 'MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer'. No clinical coverage criteria, limitations, or documentation requirements are specified in this notice.

"Administrative notice: No provider comments were received during the DL38329 comment period (10/22/2019–12/06/2019); LCD L38329 notice period begins 07/09/2020 and becomes effective 08/24/2020; LCD..."

Sign up to see full coverage criteria, indications, and limitations.